Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Slides:

Advertisements

Similar presentations

Date of download: 6/24/2016 Copyright © The American College of Cardiology. All rights reserved. From: Overview of the 2011 Food and Drug Administration.

Advertisements

Date of download: 7/1/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Scope of Coronary Heart Disease in Patients With.

Date of download: 7/8/2016 Copyright © The American College of Cardiology. All rights reserved. From: Tolerability and efficacy of carvedilol in patients.

Date of download: 11/12/2016 Copyright © The American College of Cardiology. All rights reserved. From: Epidemiology and natural history of atrial fibrillation:

Date of download: 11/13/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Reality of Heart Failure in Latin America J.

Management of mitral regurgitation. See legend for Fig

Figure 1 Estimated annual percentages of new

Figure 2 Response after initial increase in total tumour burden

Figure 3 Response after appearance of a new lesion

Figure 1 Concept of the therapeutic index

Figure 5 Schematic illustration of different clinical trial designs

Reproduced with permission from Yancy, C. W. et al. 2017

Figure 5 BMI and cardiorespiratory fitness levels

Figure 8 Implanted devices for the management of heart failure

Figure 4 BMI and mortality in patients with heart failure

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Global rates of sodium, fruit, and vegetable intake

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Three-year survival rates on the basis of body composition

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Figure 1 CAR-T-cell design

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Prevalence of HFpEF and HFrEF by age

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Nat. Rev. Cardiol. doi: /nrcardio

chemotherapy for patients with MC versus those with AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Cardiovascular risk and disease across the life-course

Figure 1 Decision tree integrating the assessment,

Johannes Steiner et al. JACC 2017;70:

Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)

Peter K. Smith, MD The Journal of Thoracic and Cardiovascular Surgery

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Figure 2 Global cost of HF per capita in 2012

Figure 2 A patient with aortic stenosis and mitral regurgitation

Figure 2 Median monthly launch price of a new anticancer drug,

Nat. Rev. Cardiol. doi: /nrcardio

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Frequency and overlap of alterations

Nat. Rev. Cardiol. doi: /nrcardio

Figure 2 Variations between planned and delivered doses of radiation

Baseline Characteristics of Cardiovascular Risk Factors and Selected Dietary Variables in a Cohort of 22,881 Men and 35,091 Women to Quintile of Fish Intakes.

Figure 2 Impaired mitochondrial capacity and function in heart failure

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Cardiol. doi: /nrcardio

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

Cumulative survival without events during 1 year in patients with preserved systolic function (left ventricular ejection fraction (LVEF) >40%) and with.

Nat. Rev. Cardiol. doi: /nrcardio

Patient selection. *This category included 10 patients with suspected tachyarrhythmia, 9 treated for cancer with cardiotoxic cytostatics and/or transthoracic.

Flow chart patient inclusion.

Figure 3 Determination of the primary site

Average left ventricular ejection fraction (LVEF) values during the 1 year of observation in patients with preserved systolic function (LVEF >40%) and.

Figure 1 Gene-expression quantification methods

Presentation transcript:

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications after anthracycline administration. Probability of patients having complete recovery of left ventricular ejection fraction decreases according to time elapsed between anthracycline administration and the start of heart failure therapy. Modiﬁed with permission from Cardinale, D. et al. J. Am. Coll. Cardiol. 55, 213–220 (2010)67. Cardinale, D. et al. J. Am. Coll. Cardiol. 55, 213–220 (2010) Zagar, T. M. et al. (2015) Breast cancer therapy-associated cardiovascular disease Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2015.171